New highly active taxoids from 9β-dihydrobaccatin-9,10-acetals. Part 4

Bioorganic and Medicinal Chemistry

Volumn 11, Issue 20, 2003, Pages 4431-4447

  Takeda, Yasuyuki ^a   Uoto, Kouichi ^a   Chiba, Jun ^a   Horiuchi, Takao ^a   Iwahana, Michio ^a   Atsumi, Ryo ^a   Ono, Chiho ^a   Terasawa, Hirofumi ^a   Soga, Tsunehiko ^a  

^a DAIICHI SANKYO CO   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

4 ACETOXY 2 BENZOYLOXY 5,20 EPOXY 1 HYDROXY 9,10 [2 (MORPHOLINO)ETHYLIDENEDIOXY]TAX 11 EN 13 YL 3 (TERT BUTOXYCARBONYLAMINO) 2 HYDROXY 3 (5 HYDROXY 2 PYRIDYL)PROPIONATE; ACETAL DERIVATIVE; PROPIONIC ACID DERIVATIVE; PYRIDINE; TAXANE DERIVATIVE; TOXOID; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG DESIGN; DRUG STRUCTURE; DRUG SYNTHESIS; HUMAN; HUMAN CELL; HYDROXYLATION; IN VITRO STUDY; LIVER MICROSOME; METABOLISM; METABOLITE;

EID: 0041833673     PISSN: 09680896     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0968-0896(03)00454-1     Document Type: Article

References (16)

1. Wani M. C., Taylor H. L., Wall M. E., Coggon P., MacPhail A. T. J. Am. Chem. Soc. 93:1971;2325.
2. Schiff P. B., Fant J., Horwitz S. B. Nature. 277:1979;665.
3. Guéritte-Voegelein F., Guénard D., Lavelle F., Le Goff M.-T., Mangatal L., Potier P. J. Med. Chem. 34:1991;992.
4. For general reviews on taxoid chemistry, see: (a) Suffness, M., Ed., Taxol® Science and Applications; CRC: New York, 1995. (b) Georg, I. G., Chen, T. T., Ojima, I., Vyas, D. M., Eds., Taxane Anticancer Agents: Basic Science and Current Status; ACS Symposium Series No. 583; American Chemical Society: Washington, DC, 1995. (c) Farina, V., Ed., The Chemistry and Pharmacology of Taxol® and its Derivatives; Elsevier: New York, 1995.
5. For general reviews on taxoid chemistry, see: (a) Suffness, M., Ed., Taxol® Science and Applications; CRC: New York, 1995. (b) Georg, I. G., Chen, T. T., Ojima, I., Vyas, D. M., Eds., Taxane Anticancer Agents: Basic Science and Current Status; ACS Symposium Series No. 583; American Chemical Society: Washington, DC, 1995. (c) Farina, V., Ed., The Chemistry and Pharmacology of Taxol® and its Derivatives; Elsevier: New York, 1995.
6. For general reviews on taxoid chemistry, see: (a) Suffness, M., Ed., Taxol® Science and Applications; CRC: New York, 1995. (b) Georg, I. G., Chen, T. T., Ojima, I., Vyas, D. M., Eds., Taxane Anticancer Agents: Basic Science and Current Status; ACS Symposium Series No. 583; American Chemical Society: Washington, DC, 1995. (c) Farina, V., Ed., The Chemistry and Pharmacology of Taxol® and its Derivatives; Elsevier: New York, 1995.
7. (a) . For review, see: Suffness M. Annu. Rep. Med. Chem. 28:1993;305 (b) Guénard D., Guéritte-Voegelein F., Potier P. Acc. Chem. Res. 26:1993;160.
8. (a) . For review, see: Suffness M. Annu. Rep. Med. Chem. 28:1993;305 (b) Guénard D., Guéritte-Voegelein F., Potier P. Acc. Chem. Res. 26:1993;160.
9. Ishiyama T., Iimura S., Ohsuki S., Uoto K., Terasawa H., Soga T. Bioorg. Med. Chem. Lett. 12:2002;1083.
10. Takeda Y., Yoshino T., Uoto K., Chiba J., Ishiyama T., Iwahana M., Jimbo T., Tanaka N., Terasawa H., Soga T. Bioorg. Med. Chem. Lett. 13:2003;185.
11. Blantz E. J. Jr., French F. A., Doamaral J. R., French D. A. J. Med. Chem. 13:1970;1124.
12. Ojima I., Habus I., Zhao M., Zucco M., Park Y. H., Sun C. M., Brigaud T. Tetrahedron. 48:1992;6985.
13. The enantiomeric excess of 13a, 13b and 22f could not be determined by HPLC analysis with a Chiralcel OD column; however, from the consideration of good yields at the coupling reaction with 16, the enantiomeric excess of each compound was assumed to be high and/or a kinetic resolution might occur.
14. Tennenson S. M., Belleau B. Can. J. Chem. 58:1980;1605.
15. PC-6/VCR29-9: PC-6 cell line, which is resistant to Vincristine®. PC-6/VP1-1: PC-6 cell line, which is resistant to VP-16 (Etoposide®).
16. Ishii M., Iwahana M., Mitsui I., Minami M., Imagawa S., Tohgo A., Ejima A. Anticancer Drugs. 11:2000;353.